AI-Generated Question Prompts for Lymphoma and Multiple Myeloma

JH
Overseen ByJessica Hahne, MA, MPH
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Washington University School of Medicine
Must be taking: Chemotherapy
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores how AI-generated question lists, known as GPT-QPL, can help patients with blood cancers, such as lymphoma and multiple myeloma, communicate more effectively with their doctors. The focus is on creating personalized questions for patients to ask during appointments, aiming to improve the information they receive and their confidence in discussions. Patients diagnosed with lymphoma or multiple myeloma who have a follow-up appointment scheduled at a participating clinic might be suitable candidates. Participants will use these AI-generated question lists during visits to assess the impact on communication and satisfaction with care. As an unphased trial, this study offers a unique opportunity to enhance communication skills and satisfaction with care.

Do I need to stop my current medications for this trial?

The trial information does not specify whether you need to stop taking your current medications. It seems focused on using AI to help with questions during appointments, so it's unlikely to require changes to your medication.

What prior data suggests that this AI-generated question prompt list is safe for patients with hematologic cancers?

This study does not test any treatments on the body. Instead, it uses a list of questions created by artificial intelligence (AI) to assist patients during doctor visits. As a result, there are no safety risks typically associated with new drugs or medical devices.

Research has shown that AI tools, like ChatGPT, can sometimes struggle to provide complete answers to specific medical questions. However, this does not pose any physical risk to patients. The main goal is to determine if these AI-generated questions can enhance patient-doctor communication and help patients feel more informed about their care.

Overall, this trial focuses on improving communication, not testing a medicine or procedure. Therefore, participants face no physical safety concerns.12345

Why are researchers excited about this trial?

Researchers are excited about the AI-generated Question Prompt List (GPT-QPL) because it offers a personalized communication tool that could significantly enhance doctor-patient interactions for those with lymphoma and multiple myeloma. Unlike traditional treatments that focus primarily on managing the disease itself, GPT-QPL aims to empower patients by helping them ask more informed questions, potentially leading to better understanding and management of their condition. This innovative approach leverages artificial intelligence to tailor question prompts to each patient's specific needs, promoting more meaningful conversations and informed decision-making in medical appointments.

What evidence suggests that this AI-generated question prompt list is effective for hematologic cancers?

Research has shown that AI-generated personalized question lists can assist patients with blood cancers, such as lymphoma and multiple myeloma, during doctor visits. In this trial, participants will receive the AI-Generated, Personalized Question Prompt List (GPT-QPL) to aid them. Studies have found that AI tools, like ChatGPT, create helpful and accurate question lists for patients. These lists increase patients' confidence and satisfaction with the information from their doctors. Evaluations of AI tools in healthcare have demonstrated their ability to generate relevant questions that enhance communication between patients and doctors. While early results are promising, ongoing research continues to explore how these AI-generated prompts can improve patient outcomes over time.46789

Who Is on the Research Team?

JH

Jessica Hahne, MA, MPH

Principal Investigator

Washington University School of Medicine

Are You a Good Fit for This Trial?

This trial is for patients with hematologic cancers like lymphoma or multiple myeloma. Participants should be interested in using an AI tool to generate personalized questions for their doctor's appointments. Specific eligibility criteria are not provided, but typically participants would need to meet certain health conditions and agree to the study procedures.

Inclusion Criteria

I can make my own medical decisions.
Able to use email (consent form will be distributed electronically through DocuSign and associated emails)
I have been diagnosed with lymphoma or multiple myeloma.
See 3 more

Exclusion Criteria

Visual impairments or English literacy limitations that would interfere with ability to engage in an intervention
I am either 18-19 years old or over 99.
I have a legal representative due to cognitive issues.
See 1 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Intervention

Participants receive an AI-generated, personalized question prompt list tailored to their individual characteristics and concerns

12 weeks
2 visits (in-person)

Follow-up

Participants are monitored for changes in communicative self-efficacy and satisfaction with information received

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • GPT-QPL
Trial Overview The trial tests an AI-generated personalized question prompt list (QPL) designed to help patients ask relevant questions during medical appointments. The QPL is tailored using WashU's HIPAA compliant ChatGPT, aiming to improve patient communication, confidence, and satisfaction with information received about their condition and treatment.
How Is the Trial Designed?
1Treatment groups
Experimental Treatment
Group I: GPT-QPL: An AI-Generated, Personalized Question Prompt ListExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Washington University School of Medicine

Lead Sponsor

Trials
2,027
Recruited
2,353,000+

Citations

An AI-Generated, Personalized Question Prompt List ...The goal of this study is to evaluate the feasibility and preliminary efficacy of an artificial intelligence (AI)-generated personalized ...
Summarizing clinical evidence utilizing large language ...We objectively assessed the abilities of four commercially available LLMs to generate synopses for six treatment regimens in multiple myeloma ...
ChatGPT, M.D.? Evaluating Chatbot Accuracy in the Fast ...Sylvester physician-evaluators assessed the responses of ChatGPT to 10 questions specific to the field of hematological cancer.
COMPARATIVE EffECTIVENESS OF HEMATOLOGISTS ...The overall score (maximum 20 points) was 18 for the Hematologist, 8 for CGPT4, 11 for CGPTo3, 16 for GF and 12 for CS. Regarding the image-specific questions: ...
Comparative analysis of the performance of the large ...This study highlights the superior performance of Open AI-o1 compared to ChatGPT-3.5 and ChatGPT-4 in addressing clinical questions related to ...
An AI-Generated, Personalized Question Prompt List ...The goal of this study is to evaluate the feasibility and preliminary efficacy of an artificial intelligence (AI)-generated personalized ...
An AI-Generated, Personalized Question Prompt List ...The goal of this study is to evaluate the feasibility and preliminary efficacy of an artificial intelligence (AI)-generated personalized ...
Study Shows ChatGPT Struggles With Patient-Specific ...A study found ChatGPT 3.5 was more likely to give incomplete or inaccurate answers to specific hematologic malignancy queries vs general ...
An AI-Generated, Personalized Question Prompt List ...An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers - Drug Trials For Money - Paid Clinical ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security